[go: up one dir, main page]

PL2861229T3 - Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową - Google Patents

Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową

Info

Publication number
PL2861229T3
PL2861229T3 PL13728758T PL13728758T PL2861229T3 PL 2861229 T3 PL2861229 T3 PL 2861229T3 PL 13728758 T PL13728758 T PL 13728758T PL 13728758 T PL13728758 T PL 13728758T PL 2861229 T3 PL2861229 T3 PL 2861229T3
Authority
PL
Poland
Prior art keywords
nicotinamide
tryptophan
pharmaceutical composition
composition containing
nicotinic acid
Prior art date
Application number
PL13728758T
Other languages
English (en)
Inventor
Georg Waetzig
Dirk Seegert
Original Assignee
Conaris Research Institute Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Research Institute Ag filed Critical Conaris Research Institute Ag
Publication of PL2861229T3 publication Critical patent/PL2861229T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL13728758T 2012-06-15 2013-06-14 Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową PL2861229T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102012011890 2012-06-15
EP13728758.7A EP2861229B1 (en) 2012-06-15 2013-06-14 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
PCT/EP2013/062363 WO2013186355A1 (en) 2012-06-15 2013-06-14 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota

Publications (1)

Publication Number Publication Date
PL2861229T3 true PL2861229T3 (pl) 2021-08-09

Family

ID=47002494

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13728758T PL2861229T3 (pl) 2012-06-15 2013-06-14 Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową

Country Status (33)

Country Link
US (2) US10426765B2 (pl)
EP (2) EP3831379A1 (pl)
JP (3) JP6855165B2 (pl)
KR (2) KR20150021071A (pl)
CN (2) CN108273064A (pl)
AR (1) AR091465A1 (pl)
AU (1) AU2013276451B2 (pl)
BR (1) BR112014030835B1 (pl)
CA (1) CA2876540C (pl)
CY (1) CY1123999T1 (pl)
DK (1) DK2861229T3 (pl)
ES (1) ES2859758T3 (pl)
HK (1) HK1204972A1 (pl)
HR (1) HRP20210090T1 (pl)
HU (1) HUE053359T2 (pl)
IL (1) IL236205B (pl)
IN (1) IN2014DN10260A (pl)
JO (1) JO3578B1 (pl)
LT (1) LT2861229T (pl)
MX (1) MX370795B (pl)
NZ (1) NZ702297A (pl)
PH (1) PH12014502744A1 (pl)
PL (1) PL2861229T3 (pl)
PT (1) PT2861229T (pl)
RS (1) RS61288B1 (pl)
RU (1) RU2657797C2 (pl)
SA (1) SA113340643B1 (pl)
SG (1) SG11201408251SA (pl)
SI (1) SI2861229T1 (pl)
SM (1) SMT202100248T1 (pl)
TW (1) TWI624260B (pl)
WO (1) WO2013186355A1 (pl)
ZA (1) ZA201408922B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2861229T1 (sl) 2012-06-15 2021-03-31 Conaris Research Institute Ag Farmacevtski sestavek, ki vsebuje nikotinsko kislino in/ali nikotinamid in/ali triptofan, za pozitivno vplivanje na črevesno mikrobioto
KR102294405B1 (ko) * 2013-06-05 2021-08-25 더 유니버시티 오브 브리티쉬 콜롬비아 항-섬유형성 화합물, 방법 및 이의 용도
US10456389B2 (en) * 2013-06-14 2019-10-29 Conaris Research Institute Ag Extended release nicotinamide formulation
EP2884282A1 (en) 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
WO2015086843A2 (en) * 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
AU2014363430A1 (en) 2013-12-13 2016-06-16 Conaris Research Institute Ag A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
EP3107553B1 (en) * 2014-02-18 2021-12-01 Universitätsklinikum Jena Methods and compositions for intestinal microenvironment transfer
CN113908074A (zh) * 2014-05-12 2022-01-11 联合利华知识产权控股有限公司 用于诱导抗微生物肽生成的烟酰胺
CN105287561A (zh) * 2015-11-25 2016-02-03 上海交通大学医学院附属瑞金医院 一种治疗溃疡性结肠炎的药物组合物
KR102450537B1 (ko) * 2016-04-14 2022-10-04 크로마덱스 아이엔씨. 유아용 조제유에서의 니코틴아미드 리보시드, 니코틴산 리보시드, 니코틴아미드 모노뉴클레오티드 및 니코티노일 화합물 유도체의 용도
JP2019513800A (ja) 2016-04-19 2019-05-30 フェリング ベスローテン フェンノートシャップ メサラジンの経口薬学的組成物
EP3445360B1 (en) * 2016-04-19 2020-11-11 CONARIS research institute AG Oral pharmaceutical compositions of nicotinamide
CN109718234A (zh) * 2017-10-31 2019-05-07 中国农业大学 L-色氨酸在缓解肠道炎症反应和屏障功能紊乱中的应用
CN108935981A (zh) * 2018-06-05 2018-12-07 西北农林科技大学 围产期奶山羊添加烟酰胺对羔羊糖脂代谢的影响及其机制
CN113438896B (zh) * 2019-02-12 2024-10-29 田中惠 婴幼儿食品或饮料、用于改善婴幼儿肠道环境的方法和用于增强婴幼儿免疫力的方法
JP7493207B2 (ja) * 2019-03-28 2024-05-31 国立大学法人東北大学 がんの予防又は治療剤
CN113398130A (zh) * 2020-03-16 2021-09-17 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） 烟酰胺用于预防和治疗胃肠道功能紊乱的用途
JP2023550994A (ja) * 2020-11-27 2023-12-06 コナリス リサーチ インスティテュート アクチェンゲゼルシャフト Ｃｏｖｉｄ－１９及びその他のウイルス感染症の患者の症状の消散までの時間を低減するためのニコチンアミド、ニコチンアミド前駆体及びニコチンアミド代謝体並びにそれらの組成物
JPWO2023002939A1 (pl) * 2021-07-19 2023-01-26
WO2023187003A1 (en) * 2022-03-30 2023-10-05 Conaris Research Institute Ag Composition comprising nicotinamide, nicotinamide precursors, nicotinamide metabolites or combinations thereof for preventing or reducing one or more post-acute symptoms of infectious diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE19524928A1 (de) * 1995-07-08 1997-01-09 Basf Ag Verfahren zur Rektifikation von Gemischen hochsiedender luft- und/oder temperaturempfindlicher Substanzen, die eine hohe Trennleistung erfordern, im Feinvakuum, sowie für dieses Verfahren geeignete Kolonnen
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5736532A (en) * 1996-02-14 1998-04-07 Furda; Ivan Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
CN1338946A (zh) * 1998-12-23 2002-03-06 G·D·瑟尔有限公司 用于心血管适应症的回肠胆汁酸转运抑制剂和烟酸类衍生物的联合形式
US6713057B1 (en) 1999-02-24 2004-03-30 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
GB0015242D0 (en) 2000-06-22 2000-08-16 Nycomed Amersham Plc Stabiliser for radiopharmaceuticals
AU2001278699A1 (en) 2000-08-08 2002-02-18 Shionogi And Co., Ltd. Inflammatory cytokine production inhibitors
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
US20060264409A1 (en) 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
EP1751096A4 (en) 2004-05-27 2009-01-07 Antibe Therapeutics Inc 4- OR 5- AMINOSALICYLIC ACID SALT
EP1811979B1 (en) * 2004-09-27 2008-11-05 Sigmoid Pharma Limited Microcapsules comprising a methylxanthine and a corticosteroid
WO2007004613A1 (ja) 2005-07-01 2007-01-11 Ajinomoto Co., Inc. 炎症性腸疾患治療薬及びＴＮＦ－α産生抑制剤
EP2026651B1 (en) * 2006-03-08 2013-04-17 Cortria Corporation Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
ITMI20061932A1 (it) 2006-10-09 2008-04-10 Carlo Ghisalberti Complessi a trasferimento di carica per uso medicale
EP1935422A1 (en) * 2006-12-20 2008-06-25 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Pharmaceutical composition comprising nicotinamide or nicotinic acid
WO2009051609A1 (en) * 2007-10-19 2009-04-23 Pardee Joel D Metabolic enhancement therapy
WO2009131537A1 (en) * 2008-04-25 2009-10-29 Karolinska Institutet Innovations Ab New therapy of treatment of the irritable bowel syndrome.
BRPI0912842A8 (pt) * 2008-05-20 2019-01-29 Cerenis Therapeutics Holding composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
CN102105171A (zh) 2008-06-02 2011-06-22 雷迪博士实验室有限公司 改进释放烟酸制剂
JP5740306B2 (ja) 2008-10-03 2015-06-24 ドクトル ファルク ファルマ ゲーエムベーハー メサラミン顆粒を用いて腸疾患を治療するための組成物および方法
JP2011121889A (ja) 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP2012102054A (ja) 2010-11-11 2012-05-31 Kyodo Milk Industry Co Ltd 腸内ポリアミン増強剤
WO2012090224A1 (en) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug
SI2861229T1 (sl) 2012-06-15 2021-03-31 Conaris Research Institute Ag Farmacevtski sestavek, ki vsebuje nikotinsko kislino in/ali nikotinamid in/ali triptofan, za pozitivno vplivanje na črevesno mikrobioto
US10456389B2 (en) 2013-06-14 2019-10-29 Conaris Research Institute Ag Extended release nicotinamide formulation
EP3445360B1 (en) 2016-04-19 2020-11-11 CONARIS research institute AG Oral pharmaceutical compositions of nicotinamide
JP2023550994A (ja) * 2020-11-27 2023-12-06 コナリス リサーチ インスティテュート アクチェンゲゼルシャフト Ｃｏｖｉｄ－１９及びその他のウイルス感染症の患者の症状の消散までの時間を低減するためのニコチンアミド、ニコチンアミド前駆体及びニコチンアミド代謝体並びにそれらの組成物

Also Published As

Publication number Publication date
RU2014148239A (ru) 2016-08-10
JP2015519388A (ja) 2015-07-09
CN108273064A (zh) 2018-07-13
US10426765B2 (en) 2019-10-01
HRP20210090T1 (hr) 2021-03-05
EP2861229A1 (en) 2015-04-22
DK2861229T3 (da) 2021-01-18
JP6855165B2 (ja) 2021-04-07
NZ702297A (en) 2016-11-25
KR20200011619A (ko) 2020-02-03
PT2861229T (pt) 2021-01-05
JP2022017332A (ja) 2022-01-25
ES2859758T3 (es) 2021-10-04
ZA201408922B (en) 2016-10-26
CN104363907A (zh) 2015-02-18
JO3578B1 (ar) 2020-07-05
PH12014502744A1 (en) 2015-02-02
IN2014DN10260A (pl) 2015-08-07
BR112014030835A2 (pt) 2017-06-27
KR102211832B1 (ko) 2021-02-02
IL236205B (en) 2020-02-27
HK1204972A1 (en) 2015-12-11
CA2876540C (en) 2022-11-29
TW201400116A (zh) 2014-01-01
HUE053359T2 (hu) 2021-06-28
JP2019069972A (ja) 2019-05-09
US20150126462A1 (en) 2015-05-07
TWI624260B (zh) 2018-05-21
EP3831379A1 (en) 2021-06-09
RS61288B1 (sr) 2021-02-26
KR20150021071A (ko) 2015-02-27
AU2013276451B2 (en) 2018-03-29
BR112014030835B1 (pt) 2022-01-11
SI2861229T1 (sl) 2021-03-31
MX2014015217A (es) 2015-03-05
RU2657797C2 (ru) 2018-06-15
SG11201408251SA (en) 2015-01-29
LT2861229T (lt) 2021-01-25
MX370795B (es) 2020-01-08
AR091465A1 (es) 2015-02-04
EP2861229B1 (en) 2020-12-23
SA113340643B1 (ar) 2019-10-06
AU2013276451A1 (en) 2015-01-15
IL236205A0 (en) 2015-01-29
US20200009124A1 (en) 2020-01-09
WO2013186355A1 (en) 2013-12-19
CY1123999T1 (el) 2022-05-27
SMT202100248T1 (it) 2021-05-07
CA2876540A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
HK1204972A1 (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota //
HK1205690A1 (en) Pharmaceutical composition and administration thereof
IL236036A0 (en) Pyridinone and pyridizinone derivatives
IL230786A (en) Heterocyclic consequence and pharmacological drug
PT3079675T (pt) Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinal
IL238060B (en) 2-aminopyridine derivatives, their preparation and pharmaceutical compositions containing them
IL256646B (en) History of azaquinazoline carboxamides and pharmaceutical preparations containing them
IL235947A (en) Solid state isonicotinamide history and their medicinal preparations
HK1187336A1 (en) Pharmaceutical composition comprising pyridone derivatives
HUE038523T2 (hu) Piridon-származék és ezt tartalmazó gyógyszerkészítmény
HK1203955A1 (zh) 反式- -癸烯酸衍生物及含有其的藥物
ZA201501095B (en) Pyridine derivative and medicine
PL399613A1 (pl) Pochodne estrów diarylowych kwasów 1-aminoalkanofosfonowych, sposób wytwarzania pochodnych estrów diarylowych kwasów 1-aminoalkanofosfonowych oraz ich zastosowanie
IL234614B (en) Pharmaceutical composition and preparation method thereof
EP2930175A4 (en) NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USES THEREFOR, AND THE DERIVATIVE THEREOF
TH1401007439A (th) องค์ประกอบทางเภสัชกรรมที่มีนิโคตินิกแอซิด และ/หรือ นิโคตินาไมด์ และ/หรือ ทริปโตฟานเพื่อการมีอิทธิพลในด้านบวกต่อจุลชีพประจำถิ่นในลำไส้